NCT00193713已完成3 期
A Randomized, Double-Blind, Olanzapine-Referenced, Parallel-Group Safety and Efficacy Study of Flexible Doses of Bifeprunox in the Long-term Treatment of Schizpohrenia (Extension of S1543003)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •diagnosis of schizophrenia
- •understand nature of study
- •able to be managed in out-patient setting for long-term bifeprunox treatment
排除标准
- •current primary diagnosis other than schizophrenia
- •suicide risk
- •diagnosis or history of substance abuse
- •uncontrolled hypertension
研究者
相似试验
已完成
3 期
Bifeprunox in the Treatment of SchizophreniaSchizophreniaNCT00193687Solvay Pharmaceuticals986
已完成
1 期
A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.SchizophreniaNCT04369391Otsuka Pharmaceutical Development & Commercialization, Inc.150
招募中
3 期
Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaSchizophreniaNCT05184335Reviva Pharmaceuticals690
终止
3 期
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypePsychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeNCT00160147Solvay Pharmaceuticals60
已完成
3 期
Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.SchizophreniaNCT00380224Wyeth is now a wholly owned subsidiary of Pfizer120